



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 21/04, C07K 14/00, C12N 15/00, 15/63, 15/85, 15/86	A1	(11) International Publication Number: WO 00/64920 (43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/US00/11272 (22) International Filing Date: 27 April 2000 (27.04.00) (30) Priority Data: 60/131,263 27 April 1999 (27.04.99) US (71) Applicant (for all designated States except US): THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3700 Market Street, Suite 300, Philadelphia, PA 19104-3147 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): LAZAR, Mitchell, A. [US/US]; 1008 Stony Lane, Gladwyne, PA 19035 (US). (74) Agents: DOYLE, Kathryn et al.; Akin, Gump, Strauss, Hauer & Feld, L.L.P., One Commerce Square, 2005 Market Street, Suite 2200, Philadelphia, PA 19103-7086 (US).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITIONS, METHODS, AND KITS RELATING TO <i>RESISTIN</i>		
(57) Abstract The invention relates to novel nucleic acids encoding a mammalian <i>resistin</i> gene, and proteins encoded thereby, whose expression is suppressed by the antidiabetic compounds thiazolidinediones. The invention further relates to methods of treating and detecting type 2 diabetes and Syndrome X comprising modulating or detecting <i>resistin</i> expression and/or production and activity of <i>resistin</i> polypeptide.		